接受 CAR-T 细胞免疫治疗的复发/难治性多发性骨髓瘤患者中体质指数与结局的复杂关联

We conducted a retrospective study of 111 patients with R/R MM who underwent CAR-T cell treatment. Using the body mass index (BMI) classification, the patients were divided into a normal-weight group (73/111) and an overweight group (38/111). We investigated the effect of BMI on CAR-T cell therapy outcomes in patients with R/R MM.

The objective remission rates after CAR-T cell infusion were 94.7% and 89.0% in the overweight and normal-weight groups, respectively. The duration of response and overall survival were not significant difference between BMI groups. Compared to normal-weight patients, overweight patients had an improved median progression-free survival. There was no significant difference in cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome between the subgroups. In terms of hematological toxicity, the erythrocyte, hemoglobin, platelet, leukocyte and neutrophil recovery was accelerated in the overweight group. Fewer patients in the overweight group displayed moderate percent CD4 and CD4/CD8 ratios compared to the normal-weight group. Furthermore, the percent CD4 ratios were positively correlated with the levels of cytokines [interleukin-2 (IL-2) (day 14), interferon gamma (IFN- ) (day 7) and tumor necrosis factor alpha (TNF- ) (days 14 and 21)] after cells infusion. On the other hand, BMI was positively associated with the levels of IFN- (day 7) and TNF- (days 14 and 21) after CAR-T cells infusion.

Overall, this study highlights the potential beneficial effect of a higher BMI on CAR-T cell therapy outcomes.